Breaking News Instant updates and real-time market news.

AVEO

Aveo Oncology

$0.74

-0.0239 (-3.13%)

07:01
06/20/17
06/20
07:01
06/20/17
07:01

AVEO says Phase 3 TIVO-3 study reaches enrollment target ahead of schedule

AVEO Oncology announced that the company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma has reached its enrollment target of 322 patients, more than two months ahead of the company's initial guidance. Tivozanib, the company's lead program, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor receptors. A pre-planned futility analysis of the TIVO-3 trial is expected around midyear 2017, with topline data expected in the first quarter of 2018. The trial, together with the previously completed TIVO-1 trial of tivozanib in the first line treatment of RCC, is designed to support regulatory approval of tivozanib in the U.S. as a first and third line treatment for RCC. The TIVO-3 trial is enrolling patients with recurrent RCC who have failed at least two prior regimens, including VEGFR-TKI therapy. Eligible patients may also have received checkpoint inhibitor therapy in earlier lines of treatment. Patients will be randomized 1:1 to receive either tivozanib or sorafenib, with no crossover between arms. The primary endpoint of the study is progression free survival. Secondary endpoints include overall survival, overall response rate, and safety and tolerability.

AVEO Aveo Oncology
$0.74

-0.0239 (-3.13%)

01/05/17
PIPR
01/05/17
NO CHANGE
Target $1.75
PIPR
Overweight
Ophthotech termination of AMD pact with AVEO not a surprise, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said that following the Phase 3 Fovista miss last month it is "not a surprise" that Ophthotech (OPHT) has terminated the tivozanib development agreement in Age-Related Macular Degeneration with AVEO Pharmaceuticals (AVEO). A CHMP approval decision for tivozanib is expected in the first half of this year, which could trigger a $4M milestone to AVEO, and The confirmatory Phase III TIVO-3 trial in 3rd-line RCC should report top-line data in 2018, noted Tenthoff, who keeps an Overweight rating and $1.75 price target on AVEO shares.
06/08/17
PIPR
06/08/17
NO CHANGE
Target $1.6
PIPR
Overweight
Safety of AVEO's tivozanib positions drug competitively, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said the safety of tivozanib, which has been confirmed by AVEO Oncology's announcement that the TiNivo trial is progressing to its Phase 2 portion, positions the drug competitively as he believes combination regimens will ultimately dominate front-line renal cell carcinoma treatment. The analyst, who expects a potential CHMP opinion on tivozanib for front-line RCC on June 23, keeps an Overweight rating and $1.60 target on AVEO shares.

TODAY'S FREE FLY STORIES

INTT

inTEST

$8.84

-0.26 (-2.86%)

15:04
01/22/18
01/22
15:04
01/22/18
15:04
Initiation
inTEST initiated  »

inTEST initiated with $11…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEPT

Neptune Technologies

$3.05

0.14 (4.81%)

15:00
01/22/18
01/22
15:00
01/22/18
15:00
Options
New positions opened in Neptune Tech February puts and calls »

New positions opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:55
01/22/18
01/22
14:55
01/22/18
14:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

PTEN

Patterson-UTI

$24.48

0.6 (2.51%)

14:54
01/22/18
01/22
14:54
01/22/18
14:54
Periodicals
Patterson-UTI confirms responding to fire at Oklahoma rig, FOX23 says »

Patterson-UTI confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

MRNS

Marinus Pharmaceuticals

$6.83

-0.05 (-0.73%)

14:50
01/22/18
01/22
14:50
01/22/18
14:50
Options
Notable call buying in Marinus Pharmaceuticals as shares see relative strength »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

, XLI

Industrial Select Sector SPDR

$79.45

-0.24 (-0.30%)

14:49
01/22/18
01/22
14:49
01/22/18
14:49
Technical Analysis
Technical Take: S&P 500 moves to new high, levels to watch »

The S&P 500 (SPX) has…

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

XLI

Industrial Select Sector SPDR

$79.45

-0.24 (-0.30%)

XLB

S&P Select Materials SPDR

$62.93

-0.35 (-0.55%)

XLY

Consumer Discretionary Sector SPDR

$106.28

0.6762 (0.64%)

XLE

Energy Select Sector SPDR

$77.78

1.4 (1.83%)

XLK

Technology Select Sector SPDR

$68.19

0.385 (0.57%)

SPY

SPDR S&P 500 ETF Trust

$281.59

1.181 (0.42%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 18

    Mar

CELG

Celgene

$102.65

0.93 (0.91%)

14:40
01/22/18
01/22
14:40
01/22/18
14:40
Options
Celgene calls outpace puts 3:1 as shares tick modestly higher »

Celgene calls outpace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

14:40
01/22/18
01/22
14:40
01/22/18
14:40
General news
Treasury Action: yields have reversed the earlier declines »

Treasury Action: yields…

GENC

Gencor Industries

14:30
01/22/18
01/22
14:30
01/22/18
14:30
Hot Stocks
Royce & Associates reports 7.37% passive stake in Gencor Industries »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPL

Buckeye Partners

$56.18

1.155 (2.10%)

14:30
01/22/18
01/22
14:30
01/22/18
14:30
Options
Bullish option flow in Buckeye Partners as shares rally »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Feb

CLVS

Clovis

$56.76

0.89 (1.59%)

14:25
01/22/18
01/22
14:25
01/22/18
14:25
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Feb

$NSD

NASDAQ Market Internals

14:17
01/22/18
01/22
14:17
01/22/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/22/18
01/22
14:16
01/22/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYBE

Cyberoptics

$17.15

0.45 (2.69%)

14:05
01/22/18
01/22
14:05
01/22/18
14:05
Hot Stocks
Royce & Associates reports 9.64% passive stake in Cyberoptics »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$34.31

0.81 (2.42%)

14:05
01/22/18
01/22
14:05
01/22/18
14:05
Options
FMC Technologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CTB

Cooper Tire

$39.65

-0.7 (-1.73%)

14:04
01/22/18
01/22
14:04
01/22/18
14:04
Hot Stocks
Royce & Associates reports 5.14% passive stake in Cooper Tire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTG

Computer Task Group

$5.09

0.12 (2.41%)

14:02
01/22/18
01/22
14:02
01/22/18
14:02
Hot Stocks
Breaking Hot Stocks news story on Computer Task Group »

Royce & Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$85.88

18.185 (26.87%)

14:01
01/22/18
01/22
14:01
01/22/18
14:01
Downgrade
Juno Therapeutics rating change  »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGR

Ingredion

$140.05

2.92 (2.13%)

13:47
01/22/18
01/22
13:47
01/22/18
13:47
Hot Stocks
Ingredion promotes Anthony DeLio to SVP, corporate strategy »

Ingredion Incorporated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

ADSK

Autodesk

$115.29

2.74 (2.43%)

13:45
01/22/18
01/22
13:45
01/22/18
13:45
Options
Autodesk call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOB

Globant

$47.41

-0.86 (-1.78%)

13:44
01/22/18
01/22
13:44
01/22/18
13:44
Hot Stocks
Breaking Hot Stocks news story on Globant »

JP Morgan Chase reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

NWSA

News Corp.

$17.22

0.21 (1.23%)

, NWS

News Corp

$17.55

0.15 (0.86%)

13:39
01/22/18
01/22
13:39
01/22/18
13:39
Hot Stocks
News Corp. chairman Murdoch makes case for carriage fee for trusted publishers »

News Corp. (NWSA) issued…

NWSA

News Corp.

$17.22

0.21 (1.23%)

NWS

News Corp

$17.55

0.15 (0.86%)

FB

Facebook

$181.29

1.49 (0.83%)

GOOG

Alphabet

$1,137.51

7.72 (0.68%)

GOOGL

Alphabet Class A

$1,143.50

7.53 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

  • 18

    Mar

W

Wayfair

$90.98

3.135 (3.57%)

13:35
01/22/18
01/22
13:35
01/22/18
13:35
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

13:35
01/22/18
01/22
13:35
01/22/18
13:35
General news
Treasury Action: yields rebounded towards highs »

Treasury Action: yields…

JNJ

Johnson & Johnson

$147.76

0.4 (0.27%)

, PG

Procter & Gamble

$91.66

0.59 (0.65%)

13:33
01/22/18
01/22
13:33
01/22/18
13:33
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$147.76

0.4 (0.27%)

PG

Procter & Gamble

$91.66

0.59 (0.65%)

VZ

Verizon

$52.87

0.955 (1.84%)

KMB

Kimberly-Clark

$116.54

1.0536 (0.91%)

TRV

Travelers

$137.87

0.02 (0.01%)

FITB

Fifth Third

$32.50

0.33 (1.03%)

HBAN

Huntington Bancshares

$15.81

0.3 (1.93%)

WAT

Waters

$214.03

3.31 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 06

    Feb

  • 13

    Feb

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.